Patients Reframing obesity beyond stigma and simplicity Deep Dive editor Eloise McLennan reports on Novo Nordisk's inaugural Weight Talks Summit in London.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
News NHS to offer Wegovy to a million more people in England The NHS in England will make Novo Nordisk's Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.
News Novo hits back at rivals with cut-price Wegovy subscriptions Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers.
News Novo unveils first data for 'triple G' agonist in diabetes Novo Nordisk has reported the first clinical data with its triple G agonist for diabetes, in China, as it starts an international trials programme.
News FDA approves higher Wegovy dose via 4th priority voucher The US FDA has approved a fourth product via its new National Priority Voucher Programme - a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
